{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:35:50Z","timestamp":1757619350057,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:sec>\n            <jats:title>Hintergrund<\/jats:title>\n            <jats:p>Systemisch entz\u00fcndliche rheumatische Erkrankungen gehen h\u00e4ufig mit einer hohen Morbidit\u00e4t und teils schweren chronischen Verl\u00e4ufen einher. Sie erfordern fr\u00fchzeitige und effektive Behandlungsstrategien, um irreversible Sch\u00e4den zu verhindern. Eine medikament\u00f6se Immunsuppression ist nicht bei allen Patient:innen m\u00f6glich. In solchen F\u00e4llen ist die Anwendung alternativer Therapien wie der Immunadsorption (IA) von besonderem Interesse. Trotz positiver klinischer Erfahrungen ist die Datenlage zur Anwendung der IA bei rheumatischen Erkrankungen begrenzt.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ziel der Arbeit<\/jats:title>\n            <jats:p>Ziel war die Analyse von Anwendung, Wirksamkeit und Sicherheit der IA unter Alltagsbedingungen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material und Methoden<\/jats:title>\n            <jats:p>Im Rahmen dieser retrospektiven Untersuchung wurden 373\u00a0Immunadsorptionsbehandlungen (IA) bei 31\u00a0Patient:innen mit verschiedenen rheumatischen Erkrankungen durchgef\u00fchrt.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ergebnisse und Diskussion<\/jats:title>\n            <jats:p>Die Ergebnisse zeigen, dass die IA \u00fcberwiegend in Kombination mit anderen medikament\u00f6sen Verfahren eingesetzt wurde\u00a0\u2013 h\u00e4ufig als \u201eBridging-Therapie\u201c oder Ultima Ratio in komplexen F\u00e4llen. Die Behandlung zeigte ein gutes Sicherheitsprofil; bei 25\u202f% der Patient:innen traten vorwiegend milde Nebenwirkungen wie Blutdruckabf\u00e4lle auf. Die IA f\u00fchrte zu einer signifikanten Reduktion der Immunglobulinspiegel. In 48\u202f% der F\u00e4lle konnte ein positiver klinischer Therapieeffekt beobachtet werden. K\u00fcrzere Intervalle zwischen den Behandlungen waren mit einem besseren Ansprechen assoziiert (<jats:italic>p<\/jats:italic>\u202f=\u20090,004). Ein Zusammenhang zwischen einem positiven Therapieeffekt und der begleitenden Glukokortikoidtherapie konnte nicht festgestellt werden (<jats:italic>p<\/jats:italic>\u202f=\u20090,611), was auf einen potenziell eigenst\u00e4ndigen Effekt der IA hinweist.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Schlussfolgerung<\/jats:title>\n            <jats:p>Die IA kann somit eine wertvolle Erg\u00e4nzung im Rahmen individualisierter Therapieans\u00e4tze darstellen und sollte in zuk\u00fcnftigen Studien weiter evaluiert werden.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00393-025-01677-1","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T09:00:59Z","timestamp":1753174859000},"page":"452-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunadsorption bei rheumatischen Autoimmunerkrankungen: eine alternative Therapieoption","Immunoadsorption in rheumatic autoimmune diseases: an alternative treatment option"],"prefix":"10.1007","volume":"84","author":[{"given":"Konstantinos","family":"Triantafyllias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Kathrin","family":"Dapper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1677_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/OARRR.S34616","volume":"5","author":"R Bambauer","year":"2013","unstructured":"Bambauer\u00a0R, Latza\u00a0R, Bambauer\u00a0C, Burgard\u00a0D, Schiel\u00a0R (2013) Therapeutic apheresis in autoimmune diseases. Open Access Rheumatol 5:93\u2013103. https:\/\/doi.org\/10.2147\/OARRR.S34616","journal-title":"Open Access Rheumatol"},{"issue":"3","key":"1677_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/ard.2007.078360","volume":"66","author":"MF Bakker","year":"2007","unstructured":"Bakker\u00a0MF, Jacobs\u00a0JWG, Verstappen\u00a0SMM, Bijlsma\u00a0JWJ (2007) Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 66(3):56\u201360. https:\/\/doi.org\/10.1136\/ard.2007.078360","journal-title":"Ann Rheum Dis"},{"key":"1677_CR3","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/rheumatology\/keaa537","volume":"60","author":"M Mitratza","year":"2021","unstructured":"Mitratza\u00a0M, Klijs\u00a0B, Hak\u00a0AE, Kardaun\u00a0JWPF, Kunst\u00a0AE (2021) Systemic autoimmune disease as a\u00a0cause of death: mortality burden and comorbidities. Rheumatology 60:1321\u20131330. https:\/\/doi.org\/10.1093\/rheumatology\/keaa537","journal-title":"Rheumatology"},{"key":"1677_CR4","unstructured":"WHO Rheumatoid arthritis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/Rheumatoid-arthritis (Erstellt: 28. Juli 2023). Zugegriffen: 21. Sept. 2023"},{"key":"1677_CR5","unstructured":"AWMF S2e-Leitlinie Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/060-004 (Erstellt: 1. Apr. 2018). Zugegriffen: 21. Sept. 2023"},{"key":"1677_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","volume":"81","author":"G Nagy","year":"2022","unstructured":"Nagy\u00a0G, Roodenrijs\u00a0NMT, Welsing\u00a0PMJ, Kedves\u00a0M, Hamar\u00a0A, van der Goes\u00a0MC et\u00a0al (2022) EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 81:20\u201333. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220973","journal-title":"Ann Rheum Dis"},{"key":"1677_CR7","unstructured":"Albrecht. S1-Leitlinie: Medikament\u00f6sen Therapie der rheumatoiden Arthritis"},{"key":"1677_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.transci.2017.08.012","volume":"56","author":"K Yamaji","year":"2017","unstructured":"Yamaji\u00a0K (2017) Immunoadsorption for collagen and rheumatic diseases. Transfus Apher Sci 56:666\u2013670. https:\/\/doi.org\/10.1016\/j.transci.2017.08.012","journal-title":"Transfus Apher Sci"},{"key":"1677_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","volume":"17","author":"AY Chen","year":"2021","unstructured":"Chen\u00a0AY, Wolchok\u00a0JD, Bass\u00a0AR (2021) TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol 17:213\u2013223. https:\/\/doi.org\/10.1038\/s41584-021-00584-4","journal-title":"Nat Rev Rheumatol"},{"key":"1677_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jaci.2023.01.012","volume":"151","author":"R Labrosse","year":"2023","unstructured":"Labrosse\u00a0R, Haddad\u00a0E (2023) Immunodeficiency secondary to biologics. J\u00a0Allergy Clin Immunol 151:686\u2013690. https:\/\/doi.org\/10.1016\/j.jaci.2023.01.012","journal-title":"J Allergy Clin Immunol"},{"key":"1677_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1517\/13543784.9.9.2017","volume":"9","author":"N Braun","year":"2000","unstructured":"Braun\u00a0N, Bosch\u00a0T (2000) Immunoadsorption, current status and future developments. Expert Opin Investig Drugs 9:2017\u20132038. https:\/\/doi.org\/10.1517\/13543784.9.9.2017","journal-title":"Expert Opin Investig Drugs"},{"key":"1677_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1526-0968.2001.005002079.x","volume":"5","author":"RM Gendreau","year":"2001","unstructured":"Gendreau\u00a0RM (2001) A\u00a0randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis. Ther Apher 5:79\u201383","journal-title":"Ther Apher"},{"issue":"10","key":"1677_CR13","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/1529-0131","volume":"42","author":"DT Felson","year":"1999","unstructured":"Felson\u00a0DT, LaValley\u00a0MP, Baldassare\u00a0AR, Block\u00a0JA, Caldwell\u00a0JR, Cannon\u00a0GW et\u00a0al (1999) The Prosorba column for treatment of refractory rheumatoid arthritis: a\u00a0randomized, double-blind, sham-controlled trial. Arthritis Rheum 42(10):2153\u20132159. https:\/\/doi.org\/10.1002\/1529-0131 (\u30082153::AID-ANR16\u30093.0.CO;2\u2011W.)","journal-title":"Arthritis Rheum"},{"key":"1677_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jbspin.2004.02.009","volume":"72","author":"P Poullin","year":"2005","unstructured":"Poullin\u00a0P, Announ\u00a0N, Mugnier\u00a0B, Guis\u00a0S, Roudier\u00a0J, Lef\u00e8vre\u00a0P (2005) Protein\u00a0A-immunoadsorption (Prosorba column) in the treatment of rheumatoid arthritis. Joint Bone Spine 72:101\u2013103. https:\/\/doi.org\/10.1016\/j.jbspin.2004.02.009","journal-title":"Joint Bone Spine"},{"key":"1677_CR15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/rheumatology\/keaa537","volume":"60","author":"M Mitratza","year":"2021","unstructured":"Mitratza\u00a0M, Klijs\u00a0B, Hak\u00a0AE, Kardaun\u00a0JWPF, Kunst\u00a0AE (2021) Systemic autoimmune disease as a\u00a0cause of death: mortality burden and comorbidities. Rheumatology 60:1321\u20131330. https:\/\/doi.org\/10.1093\/rheumatology\/keaa537","journal-title":"Rheumatology"},{"key":"1677_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1046\/j.1526-0968.2001.00370.x","volume":"5","author":"G Matic","year":"2001","unstructured":"Matic\u00a0G, Bosch\u00a0T, Ramlow\u00a0W (2001) Background and indications for protein A\u2011based extracorporeal immunoadsorption. Ther Apher 5:394\u2013403","journal-title":"Ther Apher"},{"key":"1677_CR17","unstructured":"Kassen\u00e4rztliche Bundesvereinigung. Therapeutische H\u00e4mapheresen (selektive Verfahren mit Plasmadifferentialtrennung). https:\/\/www.g-ba.de\/downloads\/40-268-240\/HTA-Apheresen.pdf (Erstellt: 25. Juli 2003). Zugegriffen: 17. Dez. 2023"},{"key":"1677_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1744-9987.2006.00362.x","volume":"10","author":"K Sugimoto","year":"2006","unstructured":"Sugimoto\u00a0K, Yamaji\u00a0K, Yang\u00a0K\u2011S, Kanai\u00a0Y, Tsuda\u00a0H, Hashimoto\u00a0H (2006) Immunoadsorption plasmapheresis using a\u00a0phenylalanine column as an effective treatment for lupus nephritis. Ther Apher Dial 10:187\u2013192. https:\/\/doi.org\/10.1111\/j.1744-9987.2006.00362.x","journal-title":"Ther Apher Dial"},{"key":"1677_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/1744-9987.13663","volume":"26","author":"K Fuchs","year":"2022","unstructured":"Fuchs\u00a0K, Rummler\u00a0S, Ries\u00a0W, Helmschrott\u00a0M, Selbach\u00a0J, Ernst\u00a0F et\u00a0al (2022) Performance, clinical effectiveness, and safety of immunoadsorption in a\u00a0wide range of indications. Ther Apher Dial 26:229\u2013241. https:\/\/doi.org\/10.1111\/1744-9987.13663","journal-title":"Ther Apher Dial"},{"key":"1677_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0955-3886(94)90174-0","volume":"15","author":"M Bel\u00e0k","year":"1994","unstructured":"Bel\u00e0k\u00a0M, Borberg\u00a0H, Jimenez\u00a0C, Oette\u00a0K (1994) Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci 15:419\u2013422. https:\/\/doi.org\/10.1016\/0955-3886(94)90174-0","journal-title":"Transfus Sci"},{"key":"1677_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1567-5688(09)71824-0","volume":"10","author":"P Biesenbach","year":"2009","unstructured":"Biesenbach\u00a0P, Schmaldienst\u00a0S, Smolen\u00a0JS, H\u00f6rl\u00a0WH, Derfler\u00a0K, Stummvoll\u00a0GH (2009) Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity. Atheroscler Suppl 10:114\u2013121. https:\/\/doi.org\/10.1016\/S1567-5688(09)71824-0","journal-title":"Atheroscler Suppl"},{"key":"1677_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood-2002-01-0128","volume":"100","author":"A Goldammer","year":"2002","unstructured":"Goldammer\u00a0A, Derfler\u00a0K, Herkner\u00a0K, Bradwell\u00a0AR, H\u00f6rl\u00a0WH, Haas\u00a0M (2002) Influence of plasma immunoglobulin level on antibody synthesis. Blood 100:353\u2013355. https:\/\/doi.org\/10.1182\/blood-2002-01-0128","journal-title":"Blood"},{"key":"1677_CR23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/JLB.3RI0519-161R","volume":"106","author":"R Blandino","year":"2019","unstructured":"Blandino\u00a0R, Secreted IgM\u00a0BN (2019) New tricks for an old molecule. J\u00a0Leukoc Biol 106:1021\u20131034. https:\/\/doi.org\/10.1002\/JLB.3RI0519-161R","journal-title":"J Leukoc Biol"},{"key":"1677_CR24","first-page":"571","volume":"10","author":"C Jorgensen","year":"1992","unstructured":"Jorgensen\u00a0C, Anaya\u00a0JM, Cognot\u00a0C, Sany\u00a0J (1992) Rheumatoid arthritis associated with high levels of immunoglobulin\u00a0a: clinical and biological characteristics. Clin Exp Rheumatol 10:571\u2013575","journal-title":"Clin Exp Rheumatol"},{"key":"1677_CR25","first-page":"301","volume":"14","author":"C Jorgensen","year":"1996","unstructured":"Jorgensen\u00a0C, Legouffe\u00a0MC, Bologna\u00a0C, Brochier\u00a0J, Sany\u00a0J (1996) IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications. Clin Exp Rheumatol 14:301\u2013304","journal-title":"Clin Exp Rheumatol"},{"key":"1677_CR26","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1046\/j.1525-1594.2000.06623.x","volume":"24","author":"R Bambauer","year":"2000","unstructured":"Bambauer\u00a0R, Schwarze\u00a0U, Schiel\u00a0R (2000) Cyclosporin\u00a0A and therapeutic plasma exchange in the treatment of severe systemic lupus erythematosus. Artif Organs 24:852\u2013856. https:\/\/doi.org\/10.1046\/j.1525-1594.2000.06623.x","journal-title":"Artif Organs"},{"key":"1677_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1525-1594.1997.tb00512.x","volume":"21","author":"R Schiel","year":"1997","unstructured":"Schiel\u00a0R, Bambauer\u00a0R, Latza\u00a0R, Klinkmann\u00a0J (1997) Cyclosporine and therapeutic plasma exchange in treatment of progressive autoimmune diseases. Artif Organs 21:983\u2013988. https:\/\/doi.org\/10.1111\/j.1525-1594.1997.tb00512.x","journal-title":"Artif Organs"},{"key":"1677_CR28","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1055\/s-2008-1068648","volume":"111","author":"HJ Gutschmidt","year":"1986","unstructured":"Gutschmidt\u00a0HJ, Euler\u00a0HH, Albrecht\u00a0J, Asbeck\u00a0F, Kleine\u00a0LH, von Klinggr\u00e4ff\u00a0C, L\u00f6ffler\u00a0H (1986) Cyclophosphamid-Stosstherapie synchronisiert mit Plasmapheresen bei rapid progredienter Glomerulonephritis. Dtsch Med Wochenschr 111:1439\u20131444. https:\/\/doi.org\/10.1055\/s-2008-1068648 ([Cyclophosphamide stosstherapy synchronized with plasmapheresis in rapidly progressive glomerulonephritis])","journal-title":"Dtsch Med Wochenschr"},{"key":"1677_CR29","first-page":"270","volume":"18","author":"PC Dau","year":"1991","unstructured":"Dau\u00a0PC, Callahan\u00a0J, Parker\u00a0R, Golbus\u00a0J (1991) Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J\u00a0Rheumatol 18:270\u2013276","journal-title":"J Rheumatol"},{"key":"1677_CR30","doi-asserted-by":"publisher","first-page":"101742","DOI":"10.1016\/j.berh.2022.101742","volume":"36","author":"K Bhamidipati","year":"2022","unstructured":"Bhamidipati\u00a0K, Wei\u00a0K (2022) Precision medicine in rheumatoid arthritis. Best Pract Res Clin Rheumatol 36:101742. https:\/\/doi.org\/10.1016\/j.berh.2022.101742","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01677-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01677-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01677-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:22:28Z","timestamp":1757265748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01677-1"}},"subtitle":["Retrospektive Erkenntnisse zur klinischen Anwendung aus dem Rheumazentrum Rheinland-Pfalz","Retrospective insights on the clinical application from the Rhineland-Palatinate Rheumatology Center"],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1677"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01677-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"2 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Triantafyllias, A.-K.\u00a0Dapper und A.\u00a0Schwarting geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}